Many individuals who could gain from statins, the cholesterol-reducing medications, are either not taking them or have stopped after starting. Healthcare providers indicate that a long list of potential side effects—often highlighted in the fine print on packages—can deter patients from using these drugs.
A recent meta-analysis aims to clarify the situation regarding these commonly prescribed, low-cost medications for preventing cardiovascular disease.
Statins are known to cause two significant side effects: muscle pain in about 1% of patients and a slight increase in blood sugar that might push some individuals toward type 2 diabetes.
However, a new analysis from The Lancet finds that out of 66 potential risks, 62 lack reliable evidence. Interestingly, participants reported similar issues whether they were on statins or a placebo. For instance, in a double-blind study, 0.2% of both statin and placebo users reported experiencing brain fog.
A thorough review spanning a decade by the Cholesterol Treatment Trialists’ Collaboration evaluated 19 large randomized clinical trials with over 122,000 participants and identified credible concerns for only four specific outcomes: alterations in liver tests, minor liver abnormalities, urine changes, and tissue swelling. These risks were deemed minimal.
Christina Reith, an associate professor at Oxford Population Health, discussed the ongoing confusion surrounding statin side effects. This uncertainty leads many individuals, even those at high risk for heart attacks or strokes, to avoid starting statins or to stop taking them. “We found no significant excess risk associated with statins for nearly all the conditions cited as potential side effects,” Reith stated.
Statins play a vital role in preventive cardiology. They can slash levels of LDL or “bad” cholesterol by half, effectively reducing the risk of heart attacks and strokes by 25%. Since brand-name versions are no longer under patent, generics cost about $40 annually in the U.S. As evidence mounts about the benefits of lowering bad cholesterol, new strategies suggest initiating statin therapy even earlier than current guidelines recommend.
Recent studies assessed risks over a 30-year period instead of the standard 10 years. A paper in Circulation: Population Health and Outcomes applied newer PREVENT equations to a demographic aged 30 to 59 and discovered that 9% faced an elevated 30-year risk of heart attacks or strokes of 20% or more. This could mean advising an additional 2.5 million adults to start on statins. Moreover, about 44% fell into an intermediate risk category.
New guidelines from the American College of Cardiology and the American Heart Association, based on these PREVENT equations, are anticipated to come out in the second quarter of this year.
While primary prevention usually emphasizes lifestyle changes like diet and exercise, there’s been a gap in understanding who might need medication sooner, particularly for individuals with high blood pressure or a family history of heart disease.
Anderson noted, “Statins consistently reduce the risk of heart attacks or strokes by about 25%. The question is whether to start them at 40 or wait another decade.”
This ongoing conversation may include discussions about side effects. Despite their efficacy in decreasing serious cardiovascular issues—a monumental advancement over the past 50 years—statins face skepticism among patients reluctant to commit to long-term medication. Similar hesitations are apparent for blood pressure treatments and new obesity drugs, with fears about muscle pain and conditions like rhabdomyolysis particularly affecting perceptions of statins.
The Lancet authors emphasize that while these four side effects are significant to consider, rhabdomyolysis remains uncommon. If confirmed, alternative cholesterol-lowering medications would be suggested. While around 1% experience milder muscular symptoms, the benefits of statins generally outweigh the risks, especially in cases already diagnosed with diabetes.
They also noted a 0.1% increased risk of abnormal liver blood tests, but no uptick in liver diseases. “Our findings show no significant excess risk for nearly all conditions listed on statin packaging,” Reith reiterated, asserting that issues such as memory loss or depression reported by some statistically cannot be attributed to statins.
Experts acknowledge that drug warnings often arise from post-marketing observations lacking proper control groups. “Legally, it makes sense but biologically, it doesn’t,” said Kausik Ray, a professor involved in public health studies.
Despite this, worries may linger in clinical settings, fueled by media reports that can sometimes exaggerate risks.
Rory Collins, a senior author from the Lancet study, recounted a personal conversation with his GP who expressed similar concerns about statin side effects. This scenario occurs frequently and contributes to why many patients at high risk for heart issues remain untreated.
Although Anderson found no surprises in the Lancet data, he believes it may provide a useful framework for doctors addressing patient concerns about less common side effects. Yet, he concludes that dispelling 62 of 66 warnings won’t necessarily quell the apprehension surrounding statins or other long-term treatments.
“This really touches on a deeper issue of trust within the medical community,” he suggested. Building trust between patients and doctors is essential, especially as widespread skepticism regarding healthcare persists.
